CYP19A1 and breast cancer: The study conducted by Matthews and colleagues, which included 1,005 postmenopausal breast cancer patients in the UK and 22,027 patients in the USA, found that women treated with aromatase inhibitors showed a higher risk of several cardiovascular outcomes compared with those in users of tamoxifen.